The big boys (big pharmas) already know about CTIX, most oncologists probably have heard of Kevetrin and ASCO will certainly add many more eyes to follow it closely, and as for institutional investors we recently had IDEAS and with further PR's there should be many, many eyes of heavy hitters following CTIX by the end of summer/early fall.  The trial so far has just been a warmup to the real action that should begin with cohort 4 and steamroll thru 6 taking us into the Oct range and that is when we should have significant price appreciation IMO.  Anything prior to that in the way of positive PR is gravy and Prurisol should be kicking into high gear by Oct. Anything under $20 come Nov would come as a complete surprise to me.  Of course, those with more  biotech investing experience may be laughing their tails off at my expectations but nobody could talk me out of my current perspective.